<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441671</url>
  </required_header>
  <id_info>
    <org_study_id>R19017M</org_study_id>
    <secondary_id>2019-002109-24</secondary_id>
    <secondary_id>KLnro 38/2019</secondary_id>
    <nct_id>NCT04441671</nct_id>
  </id_info>
  <brief_title>Oral Pyrophosphate Absorption in PXE Disease</brief_title>
  <official_title>Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hungarian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification.&#xD;
      The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi).&#xD;
      Absorption curves (pharmacokinetics), AUC0-t, Cmax and Tmax for PPi and phosphate will be&#xD;
      provided for healthy controls and PXE-patients both fasting and with standard meal intake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II oral capsulized disodium-PPi (Na2H2PPi) powder absorption study in subjects with PXE&#xD;
      (n=8-12) will be done in the ward of Internal Medicine of Tampere University Hospital and&#xD;
      University Medical Center Utrecht.&#xD;
&#xD;
      After a 10-hour fast at 8.00 a.m. 30 mg/kg (first day) and 50 mg/kg (second day) capsulized&#xD;
      dose of PPi will be given with 2 dl water. At 12.00 a.m. another capsulized 30 mg/kg (first&#xD;
      day) or 50 mg/kg (second day) single dose of PPi with a standard mixed meal (lunch) will be&#xD;
      given with 2 dl water at the time when a subject starts eating.&#xD;
&#xD;
      Plasma and urine sampling include plasma and spot urine electrolytes, creatinine, and&#xD;
      pyrophosphate. Plasma sampling will be done at 0, 15, 30, 60, 120 and 240 min after ingestion&#xD;
      of PPi. Urine spot sample will be taken at 0 and 240 min after ingestion of PPi.&#xD;
&#xD;
      Physical activity is restricted. Side-effects will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn&#xD;
  </why_stopped>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration area under the curve 0-t of pyrophosphate</measure>
    <time_frame>two days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal concentration of pyrophosphate</measure>
    <time_frame>two days</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Timepoint of maximal pyrophosphate concentration</measure>
    <time_frame>two days</time_frame>
    <description>Tmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration area under the curve 0-t of phosphate</measure>
    <time_frame>two days</time_frame>
    <description>AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal concentration of phosphate</measure>
    <time_frame>two days</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timepoint of maximal phosphate concentration</measure>
    <time_frame>two days</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pseudoxanthoma Elasticum</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disodiumpyrophosphate, capsuled powder, First day: 30 mg/kg fasting at 08.00 and with standard mixed meal at 12.00 Second day: 50 mg/kg fasting at 08.00 and with standard mixed meal at 12.00</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disodium Pyrophosphate</intervention_name>
    <description>Absorption trial</description>
    <arm_group_label>Open label</arm_group_label>
    <other_name>Na2H2PPi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (&gt;18 yrs)&#xD;
&#xD;
          -  clinically and genetically proven PXE&#xD;
&#xD;
          -  Body mass index (BMI) 18,5-34,9 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Special groups according to researchers' decision.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  No effective contraception in females in child-bearing age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasi I Nevalainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoxanthoma Elasticum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only anonymized data can be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

